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A 78-year-old currently smoking
Japanese man was diagnosed with non-
small cell lung cancer (NSCLC). The
histology was adenocarcinoma, and the
primary stage was cT2N3M0. Epider-
mal growth factor receptor (EGFR) gene
mutations were not evaluated. After he
received four courses of chemotherapy
(carboplatin and paclitaxel) and sequen-
tial radiation (60 Gy), he achieved par-
tial response. The volume of lung re-
ceiving20 Gy (V20) was 33% (Figure
1A). Seven months after finishing radia-
tion, his chest computed tomography
(CT) revealed pulmonary metastases
and pleural disseminations (Figure 1B).
The treatment started with daily admin-
istration of 150 mg erlotinib. Fourteen
days after starting administration of er-
lotinib, his chest CT revealed right lung
consolidation localized within the previ-
ously irradiated area (Figure 1C), so we
diagnosed him with radiation recall
pneumonitis induced by erlotinib (grade
3, Radiation Therapy Oncology Group
scoring criteria). Twenty-four hours af-
ter last administration of erlotinib, we
investigated his plasma concentration of
erlotinib by high-performance liquid
chromatography with ultraviolet detec-
tion as previously reported.1 The plasma
concentration of erlotinib was 3817 ng/
mL, which was very high compared
with previously reported mean con-
centration (1642.00 ng/mL).2 After he
stopped administration of erlotinib and
received systemic corticosteroid ther-
apy, his symptoms improved.
When radiotherapy is followed by
chemotherapy, subclinical damage from
irradiation can be unmasked and clini-
cally manifested. This is called radiation
recall phenomenon. Radiation recall
pneumonitis is a very rare reaction in a
previously irradiated area of pulmonary
tissue after application of a pharmaco-
logical agent.
Erlotinib is an EGFR tyrosine ki-
nase inhibitor (TKI) and has been stud-
ied in patients with NSCLC. From Food
and Drug Administration (FDA) drug
approval summary, the incidence of in-
terstitial lung disease (ILD), which is
sometimes fatal, associated with erlo-
tinib is estimated at 0.8%.3
The reaction of radiation recall
pneumonitis is similar to that of drug-
induced ILD in that both are associated
with a specific drug. No case of radia-
tion recall pneumonitis induced by erlo-
tinib has been reported. In this article,
we present a first case report of radiation
recall pneumonitis induced by erlotinib
and investigate the plasma concentration
of erlotinib.
Fatal radiation pneumonitis is not
usually observed with a lung V20 of
33%. In contrast, a case of symptomatic
pneumonitis (grade 3) from radiation
(V20 of 31%) and concurrent erlotinib
has been reported.4 Moreover, EGFR-
TKIs have been reported to act as potent
radiation sensitizers.5 From these find-
ings, erlotinib can tend to induce radia-
tion recall pneumonitis, especially in
Japanese patients.
In this case, the plasma concentra-
tion of erlotinib was very high compared
with previous reported data.2 Although
radiation recall pneumonitis induced by
erlotinib could be related to a high
plasma concentration of erlotinib, there
is no report about this relationship. The
relationship between ILD associated
with erlotinib and erlotinib plasma con-
centration is also unclear. If ILD is re-
lated to erlotinib plasma concentration,
the plasma concentration should be in-
vestigated when erlotinib is adminis-
tered to a patient with the risk factors for
ILD and the dose can be decreased.
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FIGURE 1. A. The chest X-P of the patient for planning of irradiation. The chest computed tomography (CT) of the patient.
B. 7 months after finishing radiation, his chest CT revealed pulmonary metastases and pleural disseminations (small arrows).
A large arrow indicated a primary lesion. C. 14 days after starting administration of erlotinib, his chest CT revealed right lung
consolidation localized within the previously irradiated area.
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